Pitavastatin-Incorporated Nanoparticle-Eluting Stents Attenuate In-Stent Stenosis without Delayed Endothelial Healing Effects in a Porcine Coronary Artery Model
Tóm tắt
Từ khóa
Tài liệu tham khảo
4) Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R: Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation, 2007; 115: 1051-1058
5) Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R: Vascular responses to drug eluting stents. Importance of delayed healing. Arterioscler Thromb Vasc Biol, 2007; 27: 1500-1510
6) Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R: Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation, 2007; 115: 2435-2441
7) Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R: Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol, 2008; 52: 333-342
8) Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol, 2001; 21: 1712-1719
10) Thyberg J: Re-endothelialization via bone marrow-derived progenitor cells: Still another target of statins in vascular disease. Arterioscler Thromb Vasc Biol, 2002; 22: 1509-1511
12) Yokoyama T, Miyauchi K, Kurata T, Satoh H, Daida H: Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis, 2004; 174: 253-259
14) Scheller B, Schmitt A, Bohm M, Nickenig G: Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting. Zeitschrift fur Kardiologie, 2003; 92: 1025-1028
20) Bae JH, Bassenge E, Kim KY, Synn YC, Park KR, Schwemmer M: Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. J Cardiovasc Pharmacol Ther, 2004; 9: 185-192
22) Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S, Matoba T, Sueishi K, Endo Y, Kawashima Y, Hara K, Tsujimoto H, Tominaga R, Sunagawa K: Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv, 2009; 2: 277-283
25) Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y: Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Arzneimittel-Forschung, 1997; 47: 904-909
26) Ohtani K, Usui M, Nakano K, Kohjimoto Y, Kitajima S, Hirouchi Y, Li XH, Kitamoto S, Takeshita A, Egashira K: Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther, 2004; 11: 1273-1282
29) Usui M, Egashira K, Ohtani K, Kataoka C, Ishibashi M, Hiasa K, Katoh M, Zhao Q, Kitamoto S, Takeshita A: Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J, 2002; 16: 1838-1840
33) van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation, 1996; 94: 1690-1697